Cathepsin C inhibition as a potential treatment strategy in cancer

B Korkmaz, AS Lamort, R Domain, C Beauvillain… - Biochemical …, 2021 - Elsevier
Epidemiological studies established an association between chronic inflammation and
higher risk of cancer. Inhibition of proteolytic enzymes represents a potential treatment …

Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response

K Kessenbrock, T Dau, DE Jenne - Journal of molecular medicine, 2011 - Springer
Neutrophil granulocytes are important mediators of innate immunity, but also participate in
the pathogenesis of (auto) inflammatory diseases. Neutrophils express a specific set of …

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19

F Hersi, A Sebastian, H Tarazi, V Srinivasulu… - European Journal of …, 2023 - Elsevier
The recent emergence of different SARS-CoV-2 variants creates an urgent need to develop
more effective therapeutic agents to prevent COVID-19 outbreaks. Among SARS-CoV-2 …

Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019

MY Liu, B Zheng, Y Zhang, JP Li - Chronic Diseases and …, 2020 - mednexus.org
Coronavirus disease 2019 is a major threat to public health globally. Though its
pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has …

Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone

H Jiang, P Yang, J Zhang - Frontiers in chemistry, 2022 - frontiersin.org
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the
Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos …

Structural and biochemical analysis of the dual inhibition of MG-132 against SARS-CoV-2 main protease (Mpro/3CLpro) and human cathepsin-L

E Costanzi, M Kuzikov, F Esposito, S Albani… - International journal of …, 2021 - mdpi.com
After almost two years from its first evidence, the COVID-19 pandemic continues to afflict
people worldwide, highlighting the need for multiple antiviral strategies. SARS-CoV-2 main …

Serratiopeptidase, a serine protease anti-inflammatory, fibrinolytic, and mucolytic drug, can be a useful adjuvant for management in COVID-19

C Sharma, NK Jha, MFN Meeran, CR Patil… - Frontiers in …, 2021 - frontiersin.org
The COVID-19 pandemic, which is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a public health emergency with high mortality and disability …

Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway

K Krotova, N Khodayari, R Oshins, G Aslanidi… - Scientific reports, 2020 - nature.com
There are a number of respiratory diseases characterized by the presence of excess
neutrophil elastase (NE) activity in tissues, including cystic fibrosis and chronic obstructive …

Discovery of M protease inhibitors encoded by SARS-CoV-2

HC Hung, YY Ke, SY Huang, PN Huang… - Antimicrobial agents …, 2020 - Am Soc Microbiol
ABSTRACT The coronavirus (CoV) disease 2019 (COVID-19) pandemic caused by severe
acute respiratory syndrome CoV-2 (SARS-CoV-2) is a health threat worldwide. Viral main …

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

T Kronenberger, SA Laufer, T Pillaiyar - Drug Discovery Today, 2023 - Elsevier
Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …